ERBB2 and breast carcinoma: Notably, the phase 3 clinical trial DESTINY-Breast 04 demonstrated the efficacy of trastuzumab-deruxtecan (T-Dxd), an ADC, in the treatment of metastatic HER2-low breast cancer [7].